When you think about biotech leaders, the name Biogen (BIIB-0.83%) may come to mind. Over the years, this biotechnology giant built a powerful multiple sclerosis (MS) treatment platform that has ...

Biogen's (BIIB 0.37%) biggest problem in recent times has been growth. The biotech giant's multiple sclerosis (MS) portfolio is facing more and more generic competition, and that's resulted in ...

Biogen said it will pay Reata $172.50 per share in cash, which represents a 58.9% premium to the stock's last closing price. Including debt, the deal values Reata at roughly $7.3 billion.

Two years after a big scientific swing nearly pushed Biogen to the brink, CEO Christopher Viehbacher is embarking on a corporate rethink, one that balances Biogen’s characteristic risky bets ...

L ast week, Biogen announced it will cease both the study and sale of Aduhelm, its FDA-approved monoclonal antibody for the treatment of Alzheimer’s disease. Its decision, the company explained ...

Based on these encouraging Phase 1 data, Biogen (NASDAQ:BIIB) is engaging with regulators to advance its investigational spinal muscular atrophy asset, salanersen, to registrational stage studies.

Biogen will stop selling its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster that stumbled after its launch a few years ago.. The drugmaker also said Wednesday that it ...

The new Alzheimer's disease drug made by Eisai Inc. and Biogen Inc. is capable of slowing cognitive decline by 27%, as confirmed by a peer-reviewed study.

Biogen currently owns a 10.2% stake in SAGE, and its offer price implies a ~30% premium to the company’s closing price on Friday. More on Biogen, Sage Therapeutics, etc. Biogen Holds On, But ...

Drugmaker Biogen said Wednesday it will give up its ownership of Aduhelm, the Alzheimer’s treatment drug that sparked intense criticism of the company and the Food and Drug Administration (FDA ...

Biogen said Tuesday it plans to cut about 1,000 jobs, roughly 11 percent its global workforce, to lower costs as the Cambridge biotech begins to roll out the new Alzheimer’s drug it codeveloped ...

About 2,500 people worldwide are taking the intravenous drug, which initially was priced at $56,000 a year. In the U.S., Medicare had imposed strict limits on who could get it.